On October 6, Moderna, Inc. rose 3.27% in regular trading, trading at $211.29 per share, with turnover of $411 million.

The move was primarily driven by the upcoming inclusion of Moderna in the Nasdaq-100 Index, which is expected to attract passive index fund flows and heightened market attention.

Nasdaq previously announced that Moderna will officially join the Nasdaq-100 Index before the market opens on October 9, replacing Warner Bros. Discovery. This adjustment is expected to generate passive index fund demand and serves as a key support factor for the stock in the near term. Moderna is a leader in mRNA medicine, and the company is currently advancing the commercialization of its cancer vaccine and scaling production of multiple approved infectious disease vaccines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)